David Pidduck

CBD-based pharmaceutical company MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced its third quarter financial results Thursday for the three months ended Sept. 30, 2024. Q3 Financial Highlights Net revenue totaled CA$9.8 million ($7 million), representing a 15% increase year-over...

Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced its financial results on Wednesday for the second quarter ended June 30, 2024, revealing an 8% year-over-year and 6% sequential increase to CA$10.3 million ($7.5 million). “We are...

Cannabinoids-based pharmaceutical company MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced on Thursday that it has entered into a licensing agreement with Remidose Aerosols Inc. to acquire the exclusive rights for advanced cannabis products. Under the deal, current Remidose...

MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced its financial results on Wednesday for the full year and three months ended Dec. 31, 2023. Net revenue grew to CA$33 million ($24.3 million) in 2023, from CA$22.1 million in 2022, representing roughly a 50% year-over-year increase,...

MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) has received a GMP certification for its Barrie, Ontario facility from ANVISA, the governing body of Brazil’s pharmaceutical industry. This is MediPharm's latest approval, following GMP certifications from the FDA, European Union and...

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) reported its financial results for the three months ended September 30, 2023, with a revenue of C$8.5 million. This reflects a decrease of around C$1 million sequentially but an increase of C$1.3 million over the year. CEO David Pidduck...

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) entered into a settlement agreement on September 29, 2023 to resolve a claim in connection with a commercial agreement dispute, for a total consideration value of $9 million. On January 24, 2020, MediPharm Labs filed a statement of claim in...

Cannabinoid-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced Monday its financial results for the three months ended June 30, 2023, revealing revenue of CA$9.58 million ($7.11 million) compared to CA$4.36 million in the same period last...

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) announced financial results for Q1 2023, revealing EBITDA growth over the past two years and a significant reduction in losses to CA$2.1 million. Q1 2023 Highlights Adjusted EBITDA of $2.31 million (CA $3.1 million) with the inclusion...

MediPharm Labs Corp. (OTCQX: MEDIF) (TSX:LABS) (FSE:MLZ) provided an update on progress made on the integration of VIVO Cannabis Inc.'s (OTCQB: VVCIF) operations following the completion of its plan of arrangement with VIVO, pursuant to which MediPharm acquired all of the issued and outstanding...

MediPharm Labs Corp. (TSX:LABS) (OTCQX: MEDIF) (FSE:MLZ) FY 2022 revenue was CA$22.1 million ($16.3 million), an increase of 1.8% compared to CA$21.7 million in FY 2021. FY 2022 Financial Highlights Gross loss of CA$1.9 million compared to gross loss of CA$15.4 million in FY 2021. Net loss of...

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) announced on Monday its financial results for the three months ended Sept. 30, 2022. The Canadian cannabis company grew its third-quarter sales quarter-over-quarter while reducing working capital. Subsequent to the quarter MediPharm...

MediPharm Labs Corp. (OTCQX: MEDIF) (TSX:LABS) (FSE:MLZ) Q2 2022 revenue declined 14%, to CA$4.36 million ($3,37 million), compared to revenue of CA$5.07 million in Q2 2021. Q2 2022 Financial Highlights Gross profit was a loss of CA$532,000, compared to a loss of CA$7.73 million in Q2 2021....

MediPharm Labs Corp. (OTCQX: MEDIF) (TSX:LABS) (FSE: MLZ) a pharmaceutical company specialized in precision-based cannabinoids, has been awarded a favorable summary of judgment in the Ontario Court of Justice in connection with a supply agreement dispute in the amount of $9.8 million. On January 24...

MediPharm Labs Corp. (OTCQX: MEDIF) (TSX:LABS) (FSE:MLZ) a pharmaceutical company specialized in precision-based cannabinoids, has entered into a share prchase agreement with OneLife Botanicals PTY for the sale of MediPharm Labs Australia Pty Ltd, a wholly-owned subsidiary of the company, for a...